Ashton, CH (1997). “Benzodiazepine Dependency”. In A Baum, S. Newman, J. Weinman, R. West, C. McManus. Cambridge Handbook of Psychology & Medicine. England: Cambridge University Press. pp. 376-80. http://www.benzo.org.uk/bzdep.htm2007年7月3日閲覧。
Cloos JM, Ferreira V. (January 2009). “Current use of benzodiazepines in anxiety disorders”. Current Opinion in Psychiatry22 (1): 90–95. doi:10.1097/YCO.0b013e32831a473d. PMID19122540.
Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM. et al. (Nov 2009). “Benzodiazepine dependence: focus on withdrawal syndrome.”. Ann Pharm Fr67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID19900604.
Marriott S, Tyrer P. (August 1993). “Benzodiazepine dependence. Avoidance and withdrawal”. Drug safety: an international journal of medical toxicology and drug experience.9 (2): 93-103. doi:10.2165/00002018-199309020-00003. PMID8104417.
Poulos CX; Zack M (2004). “Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers”. Behavioural pharmacology15 (7): 503-12. doi:10.1097/00008877-200411000-00006. PMID15472572.
Khanna JM, Kalant H, Weiner J, Shah G (1992). “Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance”. Pharmacol. Biochem. Behav.41 (2): 355-60. doi:10.1016/0091-3057(92)90110-2. PMID1574525.
Humphries, P; Pretorius, E; Naudé, H (2007). “Direct and indirect cellular effects of aspartame on the brain”. European Journal of Clinical Nutrition62 (4): 451-462. doi:10.1038/sj.ejcn.1602866. ISSN0954-3007.
Herlenius, Eric; Lagercrantz, Hugo (2004). “Development of neurotransmitter systems during critical periods”. Experimental Neurology190: 8–21. doi:10.1016/j.expneurol.2004.03.027. ISSN00144886.
Westbury, J; Jackson, S; Gee, P; Peterson, G (Oct 2009). “An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project”. Int Psychogeriatr22 (1): 1–11. doi:10.1017/S1041610209991128. PMID19814843.
Barthelme B, Poirot Y (November 2008). “[Anxiety level and addiction to first-time prescriptions of anxiolytics: a psychometric study]” (French). Presse Med37 (11): 1555-60. doi:10.1016/j.lpm.2007.10.019. PMID18502091.
Lucki I; Kucharik RF (1990). “Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam”. Psychopharmacology102 (3): 350-6. doi:10.1007/BF02244103. PMID1979180.
Miura S; Murasaki M (March 1992). “The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives)”. Progress in neuro-psychopharmacology & biological psychiatry16 (6): 833-45. doi:10.1016/0278-5846(92)90103-L. PMID1355301.
Woody GE; Mc Lellan AT O'Brien CP (1979). “Development of psychiatric illness in drug abusers. Possible role of drug preference”. The New England journal of medicine.301 (24): 1310–4. doi:10.1056/NEJM197912133012403. PMID41182.
Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E (1991). “Snorting benzodiazepines”. Am J Drug Alcohol Abuse17 (4): 457–68. doi:10.3109/00952999109001605. PMID1684083.
Wetterling T, Backhaus J, Junghanns K (September 2002). “[Addiction in the elderly - an underestimated diagnosis in clinical practice?]” (German). Nervenarzt73 (9): 861–6. doi:10.1007/s00115-002-1359-3. PMID12215877.
Cloos JM, Ferreira V. (January 2009). “Current use of benzodiazepines in anxiety disorders”. Current Opinion in Psychiatry22 (1): 90–95. doi:10.1097/YCO.0b013e32831a473d. PMID19122540.
Licata SC; Rowlett JK (2008). “Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.”. Pharmacology Biochemistry and Behavior90 (1): 74-89. PMID18295321.
Marriott S, Tyrer P. (August 1993). “Benzodiazepine dependence. Avoidance and withdrawal”. Drug safety: an international journal of medical toxicology and drug experience.9 (2): 93-103. doi:10.2165/00002018-199309020-00003. PMID8104417.
Poulos CX; Zack M (2004). “Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers”. Behavioural pharmacology15 (7): 503-12. doi:10.1097/00008877-200411000-00006. PMID15472572.
Khanna JM, Kalant H, Weiner J, Shah G (1992). “Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance”. Pharmacol. Biochem. Behav.41 (2): 355-60. doi:10.1016/0091-3057(92)90110-2. PMID1574525.
Allan AM, Baier LD, Zhang X (1992). “Effects of lorazepam tolerance and withdrawal on GABAA receptor-operated chloride channels”. J. Pharmacol. Exp. Ther.261 (2): 395-402. PMID1374467.
Rooke KC (1976). “The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice”. J Int Med Res4 (5): 355-9. PMID18375.
Niessen WJ, Stewart RE, Broer J, Haaijer-Ruskamp FM (February 2005). “[Reduction in the consumption of benzodiazepines due to a letter to chronic users from their own general practitioner]” (Dutch; Flemish). Ned Tijdschr Geneeskd149 (7): 356–61. PMID15751808.
Westbury, J; Jackson, S; Gee, P; Peterson, G (Oct 2009). “An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project”. Int Psychogeriatr22 (1): 1–11. doi:10.1017/S1041610209991128. PMID19814843.
Barthelme B, Poirot Y (November 2008). “[Anxiety level and addiction to first-time prescriptions of anxiolytics: a psychometric study]” (French). Presse Med37 (11): 1555-60. doi:10.1016/j.lpm.2007.10.019. PMID18502091.
Lucki I; Kucharik RF (1990). “Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam”. Psychopharmacology102 (3): 350-6. doi:10.1007/BF02244103. PMID1979180.
Rickels K; Case WG, Schweizer EE, Swenson C, Fridman RB. (1986). “Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients”. Psychopharmacology bulletin22 (2): 407-15. PMID2877472.
Lader M. (December 1987). “Long-term anxiolytic therapy: the issue of drug withdrawal”. The Journal of clinical psychiatry48: 12-6. PMID2891684.
Miura S; Murasaki M (March 1992). “The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives)”. Progress in neuro-psychopharmacology & biological psychiatry16 (6): 833-45. doi:10.1016/0278-5846(92)90103-L. PMID1355301.
Meier PJ; Ziegler WH, Neftel K (1988-03-19). “[Benzodiazepine--practice and problems of its use]”. Schweizerische medizinische Wochenschrift118 (11): 381-92. PMID3287602.
Woody GE; Mc Lellan AT O'Brien CP (1979). “Development of psychiatric illness in drug abusers. Possible role of drug preference”. The New England journal of medicine.301 (24): 1310–4. doi:10.1056/NEJM197912133012403. PMID41182.
Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E (1991). “Snorting benzodiazepines”. Am J Drug Alcohol Abuse17 (4): 457–68. doi:10.3109/00952999109001605. PMID1684083.
Wetterling T, Backhaus J, Junghanns K (September 2002). “[Addiction in the elderly - an underestimated diagnosis in clinical practice?]” (German). Nervenarzt73 (9): 861–6. doi:10.1007/s00115-002-1359-3. PMID12215877.
Humphries, P; Pretorius, E; Naudé, H (2007). “Direct and indirect cellular effects of aspartame on the brain”. European Journal of Clinical Nutrition62 (4): 451-462. doi:10.1038/sj.ejcn.1602866. ISSN0954-3007.
Herlenius, Eric; Lagercrantz, Hugo (2004). “Development of neurotransmitter systems during critical periods”. Experimental Neurology190: 8–21. doi:10.1016/j.expneurol.2004.03.027. ISSN00144886.